Featured Research

from universities, journals, and other organizations

High percentage of rheumatoid arthritis patients discontinue triple therapy, adding or substituting other drugs after two years

Date:
October 27, 2013
Source:
American College of Rheumatology (ACR)
Summary:
A high percentage of rheumatoid arthritis patients discontinue triple therapy, a combination of disease-modifying antirheumatic drugs, after one to two years, according to new research.

A high percentage of rheumatoid arthritis patients discontinue triple therapy, a combination of disease-modifying antirheumatic drugs, after one to two years, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints are the principal body parts affected by RA, inflammation can develop in other organs as well. An estimated 1.3 million Americans have RA, and the disease typically affects women twice as often as men.

Researchers used data from the National Data Bank for Rheumatic Diseases, a depository of data on rheumatic disease patients in the United States, to examine the discontinuation rates of triple therapy among RA patients. Drug discontinuation rates are an indicator of effectiveness and may be used in health economic models to determine cost-effectiveness. Triple therapy for RA includes methotrexate, sulfasalazine and hydroxychloroquine. Data on 10,156 RA patients from 1998 to 2012 were analyzed to determine what percentage of patients discontinued triple therapy, and how long they took the combination of drugs before discontinuing or adding a biologic drug.

"The 2012 ACR RA guidelines recommend that physicians add either another DMARD (or two) or an anti- TNF biologic if initial methotrexate monotherapy is not satisfactory. There have been many studies investigating the comparative effectiveness via discontinuation rates of recent treatments for RA, but little to none looking at triple or combination DMARD therapy," explains Kaleb Michaud, PhD; assistant professor, University of Nebraska Medical Center & co-director, National Data Bank for Rheumatic Diseases; and lead investigator in the study.

"Recent results of the TEAR and RACAT clinical trials demonstrate the comparable efficacy [effectiveness] of triple therapy with anti-TNF and emphasize the importance of understanding how this treatment has been used in the real-world. It is possible that these trials may result in increased usage of triple therapy."

No data was available on when triple therapy was first prescribed for these patients, so the researchers used two definitions of discontinuation. The first definition was when patients discontinued taking all three drugs. The second definition was when patients stopped taking any combination of the drugs or when they added a different drug, including biologics. Of all the patients, 388 initiated triple therapy at some point. Of those, 304 -- or 78.4 percent -- discontinued triple therapy at some point according to the second definition, with 121 immediately switching to or adding another DMARD, and 183 dropping one or two of the drugs in the combination. A total of 216 -- or 55.7 percent -- of the triple therapy patients discontinued the combination according to the second definition. The annual discontinuation rate of triple therapy by both definitions was 408 cases per 1000 person-years by the first definition and 235 cases per 1000 person years by the second definition. Median time on triple therapy was 14 months, and doubled to 28 months when using the second definition. At two years, discontinuations were at 39.1 percent and 53.4 percent by the first and second definitions respectively.

After discontinuation of triple therapy according to either definition, 59.3 percent tended to switch to or add another DMARD, while 41.2 percent added a biologic drug.

"With emphasis on reaching a targeted low-disease activity state, physicians have many drugs to choose from for treating RA patients including triple therapy. These results show that a) triple therapy has been used in a relatively small percentage of RA patients since 1998 (~1% of RA patients in the NDB), and b) patients are not on triple therapy for very long before they switch to something else," said Dr. Michaud. "It is likely that physicians add either sulfasalazine or hydroxychloroquine one at a time to see if each drug works and is tolerated before adding the next drug. Patients prefer fewer drugs and physicians are being more responsive, so if two are working, they are less likely to add a third, and if three are working, they are more likely to see if dropping one or two would still keep their RA controlled. Triple therapy is not marketed to patients nor is it taken as a single pill; this makes interpreting these higher discontinuation rates more difficult."

Patients should talk to their rheumatologists to determine their best course of treatment.


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR). Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR). "High percentage of rheumatoid arthritis patients discontinue triple therapy, adding or substituting other drugs after two years." ScienceDaily. ScienceDaily, 27 October 2013. <www.sciencedaily.com/releases/2013/10/131027123047.htm>.
American College of Rheumatology (ACR). (2013, October 27). High percentage of rheumatoid arthritis patients discontinue triple therapy, adding or substituting other drugs after two years. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2013/10/131027123047.htm
American College of Rheumatology (ACR). "High percentage of rheumatoid arthritis patients discontinue triple therapy, adding or substituting other drugs after two years." ScienceDaily. www.sciencedaily.com/releases/2013/10/131027123047.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins